Strategic News Watch — August 5, 2026
|
Eli Lilly’s raised $85–$87 billion guidance anchored a Big Pharma Q2 that rewarded GLP-1 leaders while pressing laggards to diversify, as the Senate installed a permanent CDC director and a splashy AstraZeneca–Bristol Myers Squibb merger rumor was quickly denied.
Today’s top developments:
|
What to Watch
- Lilly’s GLP-1 Distribution Land Grab — With 2026 guidance raised and a new CVS Health app channel for Zepbound and Foundayo, the open question is whether rival PBMs strike similar access deals and how the underperforming Foundayo fares against competing oral GLP-1s.
- CDC Leadership & Vaccine Policy — Erica Schwartz’s installation as the first permanent CDC director in about a year puts a spotlight on the agency’s posture toward vaccine policy, restructuring, and public-health priorities, all of which could reshape the regulatory environment for biopharma.
- Gilead’s Diversification Catalysts — Two near-term readouts will test whether the pipeline can shift a still HIV-heavy revenue mix: a Phase 2 ulcerative colitis result for emvistegrast expected later in 2026 and an FDA decision on the Arcellx-derived CAR-T anito-cel in multiple myeloma due by December 2026.
- Big-Pharma M&A Appetite — With the AstraZeneca–Bristol Myers tie-up denied and Amgen steering toward earlier-stage deals despite roughly $14 billion in cash, capital deployment against mounting patent-cliff pressure will signal whether large caps answer analysts’ push for bolder moves.
- Arrowhead’s Plozasiran sNDA — The newly purchased priority review voucher sets up a severe-hypertriglyceridemia filing for plozasiran (REDEMPLO) before year-end that would compress the FDA’s action timeline to roughly six months — a key test of its APOC3-targeting siRNA label-expansion strategy.
This brief highlights the edition’s top stories. Read the full August 5, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.